Cargando…

Aflibercept Nanoformulation Inhibits VEGF Expression in Ocular In Vitro Model: A Preliminary Report

Age-related macular degeneration (AMD) is one of the leading causes of blindness in the United States, affecting approximately 11 million patients. AMD is caused primarily by an upregulation of vascular endothelial growth factor (VEGF). In recent years, aflibercept injections have been used to comba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, Shannon J., Hirani, Anjali, Shahidadpury, Vishal, Solanki, Aum, Halasz, Kathleen, Varghese Gupta, Sheeba, Madow, Brian, Sutariya, Vijaykumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165497/ https://www.ncbi.nlm.nih.gov/pubmed/30208574 http://dx.doi.org/10.3390/biomedicines6030092

Ejemplares similares

GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status
por: Shi, Qiwen, et al.
Publicado: (2019)

Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations
por: Gupta, Deepak, et al.
Publicado: (2018)

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

First Total Synthesis and Pharmacological Potential of a Plant Based Hexacyclopeptide
por: Dahiya, Rajiv, et al.
Publicado: (2019)

Toward the Synthesis and Improved Biopotential of an N-methylated Analog of a Proline-Rich Cyclic Tetrapeptide from Marine Bacteria
por: Dahiya, Rajiv, et al.
Publicado: (2018)

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept
por: Hong, Hye Kyoung, et al.
Publicado: (2020)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories
por: Katata-Seru, Lebogang, et al.
Publicado: (2020)

Potential Albumin-Based Antioxidant Nanoformulations for Ocular Protection against Oxidative Stress
por: Kim, Daseul, et al.
Publicado: (2019)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
por: Veritti, Daniele, et al.
Publicado: (2023)

An origami paper-based nanoformulated immunosensor detects picograms of VEGF-C per milliliter of blood
por: Sun, Shuai, et al.
Publicado: (2021)

Combined Anti-Angiogenic and Anti-Inflammatory Nanoformulation for Effective Treatment of Ocular Vascular Diseases
por: Sun, Jianguo, et al.
Publicado: (2023)

Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
por: Mira, Filipe, et al.
Publicado: (2017)

Gene expression profile of the murine ischemic retina and its response to Aflibercept (VEGF-Trap)
por: Rojo Arias, Jesús Eduardo, et al.
Publicado: (2021)

Smart Nanoformulations for Brain Cancer Theranostics: Challenges and Promises
por: Ahmad, Faraz, et al.
Publicado: (2022)

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
por: Stewart, Michael W
Publicado: (2012)

Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model
por: Finley, SD, et al.
Publicado: (2015)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes—A Preliminary Study
por: Bartos, Adrian, et al.
Publicado: (2022)

Optical-Property-Enhancing Novel Near-Infrared Active Niosome Nanoformulation for Deep-Tissue Bioimaging
por: Bishnoi, Suman, et al.
Publicado: (2021)

EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE
por: Kowalczuk, Laura, et al.
Publicado: (2017)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

The use of aflibercept (VEGF trap) in mitigating sulfur mustard-induced corneal neovascularization in a rabbit model
por: Gore, Ariel, et al.
Publicado: (2023)

Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
por: Sivertsen, Magne Sand, et al.
Publicado: (2018)

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes
por: MacDonald, Douglas A., et al.
Publicado: (2016)

Potential of nanoformulations in malaria treatment
por: Chaves, Janaina Braga, et al.
Publicado: (2022)

Nematicidal Properties of Chitosan Nanoformulation
por: Mouniga, R., et al.
Publicado: (2023)

Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis
por: Souied, Eric H., et al.
Publicado: (2016)

Sequential activation of Elk-1/Egr-1/GADD45α by arsenic
por: Shi, Qiwen, et al.
Publicado: (2014)

The short-term effects of intravitreal aflibercept injections and dexamethasone implant on ocular hemodynamics in retinal vein occlusions
por: Ciloglu, Emine, et al.
Publicado: (2019)

Short‐term effect on the ocular circulation induced by unilateral intravitreal injection of aflibercept in age‐related maculopathy
por: Mursch‐Edlmayr, Anna Sophie, et al.
Publicado: (2019)

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016)

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma
por: Torimura, Takuji, et al.
Publicado: (2016)

Visual Electrodiagnostic Testing in Birdshot Chorioretinopathy
por: Tzekov, Radouil, et al.
Publicado: (2015)

Curcumin Nanoformulation for Cervical Cancer Treatment
por: Zaman, Mohd S., et al.
Publicado: (2016)

In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin, Paige, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_28qfvmlu9dgq35b306h3k3dk6k